Global Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) - Forecast Till 2023
Neuropsychiatric is the mental disorder occur due to disturbance in the function of cerebral system. Mania and hallucination are some of the major neuropsychiatric diseases. Neuropsychiatric diseases occur at any age but the paediatric neuropsychiatry is getting a huge demand due to increasing number of infants, children and adolescents suffering from neuropsychiatric diseases. Increasing prevalence of different neuropsychiatric diseases across the globe is the major driving factor for the growth of the market. While long term treatment and lack of clinical trial data for neuropsychiatric diseases may hamper the growth of the market.
Global neuropsychiatric disorders and treatment market is expected to grow at a CAGR of 6.2% during forecasted period.
Study Objectives Global neuropsychiatric disorders and treatment market
Key Players for Global neuropsychiatric disorders and treatment market
Astrazeneca (UK), GlaxoSmithKline (UK), Universal Health Services Inc. (US), Biogen (US), Boehringer Ingelheim GmbH (Germany), Eli Lilly (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Pfizer (US), Wyeth (US), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan)
Global neuropsychiatric disorders and treatment market is segmented on the basis of disorders into degenerative diseases, neurotic disorders, psychosis and others. On the basis of treatments it is segmented as shock treatment, drug treatment, others and on the basis of end users it is hospitals, clinics, research centres and others
Figure 1- Global neuropsychiatric disorders and treatment market share, by treatment
On regional basis, North America commands the largest share of global neuropsychiatric disorders and treatment market. Increasing prevalence of neuropsychiatric disorders and governmental support for the research and development of the medicines in this area are the major driving factor for the growth of the market in North America. Europe commands the second largest market followed by Asia Pacific. Asia Pacific is expected to grow at a fastest rate due to rapid development of the healthcare sector in this regions.
The report for global neuropsychiatric disorders and treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Frequently Asked Questions (FAQ) :
The global Neuropsychiatric Disorders and Treatment Market would grow with a 6.2% CAGR during the forecast period of 2019-2025.
North America would dominate the global Neuropsychiatric Disorders and Treatment Market.
The Asia Pacific market would have the fastest growth rate.
The market has players like GlaxoSmithKline (UK), AstraZeneca (UK), Boehringer Ingelheim GmbH (Germany), Universal Health Services Inc. (US), Biogen (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Otsuka Holdings Co. Ltd (Japan), Eli Lilly (US), Wyeth (US), Pfizer (US), Astellas Pharma Inc. (Japan), and others.
The Neuropsychiatric Disorders and Treatment Market types are drug treatment, shock treatment, and others.
TABLE OF CONTENTS
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY DISORDERS
5.1 DEGENERATIVE DISEASES
5.2 NEUROTIC DISORDERS
6. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY TREATMENT
6.1 SHOCK TREATMENT
6.2 DRUG TREATMENT
7. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY END USER
7.3 RESEARCH CENTRES
8. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY REGION
8.2 NORTH AMERICA
8.3.1 WESTERN EUROPE
126.96.36.199 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4.5 REPUBLIC OF KOREA
8.5 REST OF ASIA-PACIFIC
8.6 MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1.2 PRODUCT OVERVIEW
10.1.4 KEY DEVELOPMENTS
10.2.2 PRODUCT OVERVIEW
10.2.4 KEY DEVELOPMENTS
10.3 UNIVERSAL HEALTH SERVICES INC
10.3.2 PRODUCT OVERVIEW
10.3.5 KEY DEVELOPMENT
10.4 BOEHRINGER INGELHEIM GMBH
10.4.2 PRODUCT OVERVIEW
10.4.4 KEY DEVELOPMENTS
10.5 ELI LILLY
10.5.2 PRODUCT OVERVIEW
10.5.4 KEY DEVELOPMENTS
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF INDUSTRY